Immune responses to retinal autoantigens and peptides in equine recurrent uveitis.
OBJECTIVE
To test the hypothesis that autoimmune mechanisms are involved in horses in which equine recurrent uveitis (ERU) develops spontaneously.


METHODS
Material obtained from horses treated for spontaneous disease by therapeutic routine vitrectomy was analyzed for total IgG content and IgG specific for S-Antigen (S-Ag) and interphotoreceptor retinoid-binding protein (IRBP). The cellular infiltrate of the vitreous was analyzed by differential counts of cytospin preparations and flow cytometry using equine lymphocyte-specific antibodies. Antigen-specific proliferation assays were performed comparing peripheral blood lymphocytes (PBLs) with vitreal lymphocytes by stimulation with S-Ag and several S-Ag- and IRBP-derived peptides.


RESULTS
The total IgG content of specimens from horses with ERU was very high with great variability among the investigated samples (11.5 +/- 8.0 mg). Autoantibodies to S-Ag or IRBP or both were found in 72% of vitreous specimens from horses with uveitis. The leukocyte infiltrates (up to 2 x 10(8) cells per sample) were dominated by lymphocytes (>90%) in most cases (22/32). Flow cytometry showed that more than 50% of these cells were CD4(+) T cells. In vitro stimulation of vitreal lymphocytes, but not of PBL, showed a strong proliferative response to peptides derived from S-Ag or IRBP in 9 of 12 patients.


CONCLUSIONS
In the eyes of horses with ERU, IgG antibodies and autoreactive T cells specific for retinal antigens were detected. These results strongly support the hypothesis that ERU is an autoimmune-mediated disease and is highly similar to recurrent uveitis in humans in both clinical and immunologic parameters.
Deeg
C A
CA
Institute of Animal Physiology, Ludwig-Maximilians University, Munich, Germany. deeg@tiph.vetmed.uni-muenchen.de
Kaspers
B
B
Gerhards
H
H
Thurau
S R
SR
Wollanke
B
B
Wildner
G
G
D000818:Animals; D000917:Antibody Formation; D019393:Arrestin / Q000276:immunology; D001323:Autoantibodies / Q000032:analysis*; D001324:Autoantigens / Q000276:immunology*; D001327:Autoimmune Diseases / Q000276:immunology / Q000601:surgery / Q000662:veterinary*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D005136:Eye Proteins; D005434:Flow Cytometry / Q000662:veterinary; D006734:Horse Diseases / Q000276:immunology* / Q000601:surgery; D006736:Horses; D007074:Immunoglobulin G / Q000032:analysis; D016130:Immunophenotyping / Q000662:veterinary; D008213:Lymphocyte Activation; D010446:Peptide Fragments / Q000276:immunology*; D012008:Recurrence; D012160:Retina / Q000276:immunology*; D012177:Retinol-Binding Proteins / Q000276:immunology; D014605:Uveitis / Q000276:immunology / Q000601:surgery / Q000662:veterinary*; D014821:Vitrectomy / Q000662:veterinary; D014822:Vitreous Body / Q000166:cytology / Q000276:immunology; D000099214:Retinol-Binding Proteins, Interstitial
D019393:Arrestin; D001323:Autoantibodies; D001324:Autoantigens; D005136:Eye Proteins; D007074:Immunoglobulin G; D010446:Peptide Fragments; D012177:Retinol-Binding Proteins; D000099214:Retinol-Binding Proteins, Interstitial